Dear FAPI community,

It was a busy and exciting summer.

In June, SOFIE hosted the 2nd FAP Symposium at the annual SNMMI meeting in Chicago, IL. Representatives from academia and industry spoke to a filled room about the latest developments in FAP diagnostics and therapeutics. Steadily growing interest in FAP was reflected in the enthusiastic turnout. A month later, I presented on FAP at the Targeted Radiopharmaceuticals (TRP) Summit in Boston, MA. It was great seeing familiar faces and meeting new ones at both events. Our team will be attending the EANM meeting in Vienna, Austria, this September and look forward to connecting with many of you again, or maybe for the first time! If you would like to set up a meeting at EANM, please send an email to FAPIProgram@sofie.com .

We are making excellent progress in the recruitment of patients as part of SOFIE’s Phase 2 prospective clinical trials with [68Ga]FAPI-46 and [18F]FAPI-74. Additional information provided in “FAPI Clinical Development Updates” below.

Our FAPI Global Outreach Program continues to show incredible growth and we have launched our Annual Progress Report to members of the program. This tool enables us to learn about progress on all the academic projects worldwide, and a comprehensive view of the program as a whole. More info below!

As always, thank you for reading our newsletter. We sincerely appreciate your input on how this can be a better resource for the FAPI community.

Sherly Mosessian, Ph.D.

Sherly Mosessian, Ph.D., Chief Scientific Officer


SOFIE hosted another successful FAP symposium on June 25 at this year’s annual SNMMI meeting in Chicago, IL. The event, “FAP Radioligands for Imaging and Therapy”, featured a full slate of academic and industry experts sharing the latest developments in the FAP space. Several global leaders also shared perspectives on FAP in their specific regions. The 2-hour session was recorded and can be viewed here.

(LEFT: FAP Symposium audience; RIGHT: Symposium Co-Moderators Drs. Elcin Zan and Frederik L. Giesel)
(LEFT: FAP Symposium audience; MIDDLE: Symposium Co-Moderators Drs. Elcin Zan and Frederik L. Giesel; RIGHT: Keynote Speaker Professor Rod Hicks and attendees)


FAPI Clinical Development Aug 2023


Each newsletter will feature recent FAPI publications.

Diagnostic Performance of Positron Emission Tomography with FAP
Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
Head-to-Head Intra-Individual Comparison of FAP


For those of you who are in our Global Outreach program, thank you for your participation. In accordance with the terms of your MTA with iTheranostics/SOFIE, we will be sending out an annual progress report. Please be on the lookout and complete the short questionnaire. We appreciate this partnership and wish you all the best with your research progress in utilizing FAPI.

FAPI Global Outreach Program

SOFIE has engaged with institutions globally to unlock FAPI’s clinical utility potential.

Learn more about how you can participate.

Copyright 2023 SOFIE CO. / ITHERANOSTICS INC. (21000 Atlantic Blvd. Suite 730  Dulles, VA  20166) all rights reserved.  The text or images in the newsletter may not be copied or distributed without prior permission of SOFIE. The SOFIE logo is a registered trademark of SOFIE CO. / ITHERANOSTICS INC., in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners. You have received this mail because you have subscribed for a newsletter at www.sofie.com or because you are an existing client or partner of SOFIE. If you no longer wish to receive these emails, click here to opt out.  This newsletter is meant to serve as an informational document as a service to our customers. The content or material provided is for informational purposes only and should and should not be construed as medical, legal, financial, investment, or other professional advice or opinion. SOFIE does not offer personalized medical advice or patient-specific treatment advice.